The Relationship Between Blood Sugar Levels and Cardiovascular Disease. Ann Intern Med. 2004;141:I-12. doi: 10.7326/0003-4819-141-6-200409210-00001
Download citation file:
Published: Ann Intern Med. 2004;141(6):I-12.
Diabetes interferes with the body's ability to store energy from food. The pancreas makes a substance called insulin that helps the body turn food into stored energy. Type 1 diabetes (juvenile diabetes) occurs when the pancreas stops making insulin. In type 2 diabetes (adult-onset diabetes), the body makes adequate amounts of insulin but cannot use it normally. In both cases, the result is high blood sugar levels. Over time, high blood sugar levels can lead to a number of complications, including blindness, kidney failure, nerve damage, and cardiovascular disease (heart disease and stroke). Fortunately, good care with diet, exercise, and medications to control blood sugar levels clearly prevents or delays the development of diabetes-related blindness, kidney failure, and nerve damage. The relationship between blood sugar control and cardiovascular disease is less clear. Glycosylated hemoglobin concentration is a blood test that measures blood sugar control over the previous 3 months.
To determine whether glycosylated hemoglobin levels are associated with cardiovascular disease and death from any cause in adults with and without with diabetes.
4662 men and 5570 women who were 45 to 79 years of age and who lived in Norfolk, United Kingdom. The people in this study were participating in a larger study of cancer risks.
During 1995 to 1997, the researchers collected blood specimens to measure glycosylated hemoglobin levels and asked patients about cardiovascular risk factors, such as smoking, high blood pressure, and diabetes. The researchers then followed patients through 2003 and collected information about who developed cardiovascular disease (such as heart disease or stroke) and who died.
During the study, 806 people developed cardiovascular disease and 521 died. The greater a person's glycosylated hemoglobin levels were at the start of the study, the more likely they were to develop cardiovascular disease or die. The level of glycosylated hemoglobin was associated with these events, even in people who did not have diabetes and who had glycosylated hemoglobin levels within the normal range.
This study cannot determine whether treatment to lower glycosylated hemoglobin levels would lower a person's chance of cardiovascular disease or death.
Glycosylated hemoglobin levels are associated with cardiovascular disease and death, even among people who do not have diabetes.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only